ZOGENIX, INC. (NASDAQ:ZGNX) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

ZOGENIX, INC. (NASDAQ:ZGNX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07

Submission of Matters to a Vote of Security Holders
The Annual Meeting of Stockholders of Zogenix, Inc. (the Company)
was held on May 23, 2017. Represented at the meeting were
19,391,220 shares, or 78.14%, of the Companys 24,813,544 shares of
common stock outstanding and entitled to vote at the meeting. Set
forth below are the final voting results for the actions taken by
the stockholders at the meeting.
Proposal 1 Election of Directors
The Company’s stockholders elected each of the following directors
to hold office until the 2020 Annual Meeting of Stockholders with
each receiving the following votes:
Director Name
Votes For
Votes Withheld
Broker Non-Votes
Louis C. Bock
14,718,876
101,579
4,570,765
Cam L. Garner
14,722,876
97,579
4,570,765
Mark Wiggins
14,727,511
92,944
4,570,765
In addition to the directors elected above, James B. Breitmeyer,
M.D., Ph.D., Roger L. Hawley, Erle T. Mast and Renee P. Tannenbaum,
Pharm.D. continue to serve as directors after the annual meeting.
Proposal 2 Ratification of Selection of Ernst Young LLP as
Independent Registered Public Accounting Firm for the Year Ending
December 31, 2017
The Companys stockholders ratified the selection of Ernst Young LLP
as the Companys independent registered public accounting firm for
the year ending December 31, 2017, with the following vote:
Votes For
Votes Against
Abstentions
Broker Non-Votes
19,347,998
29,919
13,303
N/A
Proposal 3 Advisory Vote to Approve Compensation of the Named
Executive Officers
The Companys stockholders approved, on an advisory (non-binding)
basis, the compensation of the Companys named executive officers,
as disclosed in the Company’s 2017 Proxy Statement, with the
following vote:
Votes For
Votes Against
Abstentions
Broker Non-Votes
14,598,857
199,357
22,241
4,570,765
Proposal 4 Advisory Vote on the Frequency of Future Advisory
Votes to Approve Executive Compensation
The Companys stockholders recommended, by non-binding vote, that a
stockholder vote to approve the compensation of the Company’s
named executive officers should occur every year, with the
following vote:
Every One Year
Every Two Years
Every Three Years
Abstentions
Broker Non-Votes
13,939,684
8,574
861,322
10,875
4,570,765
In accordance with the stockholders’ recommendation, the Company
has determined that an advisory vote on the compensation of the
Company’s named executive officers will be conducted every year,
until the next advisory vote on the frequency of the advisory vote
on the compensation of the Company’s named executive officers.


About ZOGENIX, INC. (NASDAQ:ZGNX)

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. Its lead product candidate, ZX008, is a low-dose fenfluramine. The Company is also engaged in the development of Relday, which is a long-acting injectable formulation of risperidone indicated for the treatment of symptoms of schizophrenia and bipolar disorder in adults and teenagers 13 years of age and older. The Company is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, which it sells to Endo Ventures Bermuda Limited and Endo Ventures Limited. Its DosePro technology is a drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle.

ZOGENIX, INC. (NASDAQ:ZGNX) Recent Trading Information

ZOGENIX, INC. (NASDAQ:ZGNX) closed its last trading session down -0.35 at 12.75 with 153,593 shares trading hands.